Stoke Therapeutics (STOK) News Today $18.21 +1.04 (+6.06%) Closing price 04:00 PM EasternExtended Trading$18.30 +0.09 (+0.49%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Stoke Therapeutics Up Today?Toggle Visibility of Why Is Stoke Therapeutics Up Today?Stoke Therapeutics, Inc. (NASDAQ:STOK) is trading higher today following a flurry of analyst upgrades and stronger-than-expected earnings results. Positive Sentiment: Chardan Capital restated a “Buy” rating with a $24.00 price target on STOK. Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital Positive Sentiment: Wedbush raised its price target on STOK shares to $22.00 and maintained an “Outperform” rating. Wedbush Increases Stoke Therapeutics (NASDAQ:STOK) Price Target to $22.00 Positive Sentiment: Stoke Therapeutics shares gapped up after reporting stronger-than-expected quarterly earnings. Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Strong Earnings Positive Sentiment: Cantor Fitzgerald boosted its FY2025 EPS forecast on STOK to $0.27 from ($0.34) and reiterated a “Strong-Buy” rating. Positive Sentiment: HC Wainwright lifted its Q3 2025 EPS estimate for STOK to ($0.60) from ($0.69), maintaining a “Buy” rating and a $35.00 target. Positive Sentiment: Leerink Partners edged up its Q3 2025 EPS forecast for STOK to ($0.64) from ($0.65). Positive Sentiment: Wedbush increased its Q3 2025 EPS estimate for STOK to ($0.57) from ($0.58) and reaffirmed its “Outperform” rating. Positive Sentiment: Chardan Capital reiterated its “Buy” rating on STOK shares. Chardan Capital Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK) Positive Sentiment: STOK hit a new 12-month high following an analyst upgrade. Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High on Analyst Upgrade Positive Sentiment: Yahoo Finance reported that STOK beat second-quarter 2025 expectations. Stoke Therapeutics Second Quarter 2025 Earnings: Beats Expectations Neutral Sentiment: MSN highlighted Stoke Therapeutics among stocks with rising relative price strength. Stocks With Rising Relative Price Strength: Stoke Therapeutics Negative Sentiment: Leerink Partners trimmed its FY2029 EPS estimate for STOK to $0.30 from $0.35. Negative Sentiment: STOK reported Q2 EPS of ($0.40), missing the consensus by $0.31. Stoke Therapeutics (NASDAQ:STOK) Issues Quarterly Earnings Results Posted 1h agoAI Generated. May Contain Errors. STOK Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan CapitalAugust 15 at 1:03 PM | marketbeat.comWedbush Increases Stoke Therapeutics (NASDAQ:STOK) Price Target to $22.00August 15 at 11:14 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Strong EarningsAugust 15 at 10:28 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up on Better-Than-Expected EarningsAugust 15 at 2:35 AM | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High on Analyst UpgradeAugust 15 at 2:17 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Issues Quarterly Earnings ResultsAugust 14 at 4:36 PM | marketbeat.comStoke Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 14 at 12:54 PM | finance.yahoo.comStocks With Rising Relative Price Strength: Stoke TherapeuticsAugust 14 at 12:54 PM | msn.comChardan Capital Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK)August 14 at 3:49 AM | americanbankingnews.comWhere Stoke Therapeutics Stands With AnalystsAugust 13 at 11:30 PM | benzinga.comStoke Therapeutics Advances RNA Medicine with Strong Q2 ResultsAugust 13 at 5:05 AM | msn.comXTX Topco Ltd Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)August 13 at 3:14 AM | marketbeat.comStoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To ExpectAugust 12 at 12:04 AM | finance.yahoo.comStoke Therapeutics reports Q2 EPS (40c), consensus (54c)August 12 at 12:04 AM | msn.comStoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet SyndromeAugust 12 at 7:03 PM | finance.yahoo.comStoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 12 at 7:03 PM | finance.yahoo.comA Look Ahead: Stoke Therapeutics's Earnings ForecastAugust 11, 2025 | benzinga.comStoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 6, 2025 | businesswire.comStoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 4,504 SharesAugust 6, 2025 | marketbeat.comStoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on WednesdayAugust 5, 2025 | americanbankingnews.comThe Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, HungaryAugust 1, 2025 | msn.comStoke Therapeutics (STOK) to Release Quarterly Earnings on WednesdayJuly 30, 2025 | marketbeat.com28,600 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Bought by Dauntless Investment Group LLCJuly 29, 2025 | marketbeat.comStoke Therapeutics Inc. Stock Grades | STOK | Barron'sJuly 28, 2025 | barrons.comStoke Therapeutics (NASDAQ:STOK) Shares Up 18.1% - Here's WhyJuly 22, 2025 | marketbeat.comKennondale Capital Management LLC Acquires Shares of 42,100 Stoke Therapeutics, Inc. (NASDAQ:STOK)July 22, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 4.3% - Here's WhyJuly 21, 2025 | marketbeat.comJefferies Initiates Coverage of Stoke Therapeutics (STOK) with Buy RecommendationJuly 19, 2025 | msn.comJefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drugJuly 19, 2025 | finance.yahoo.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up - What's Next?July 18, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Now Covered by Analysts at Jefferies Financial GroupJuly 18, 2025 | marketbeat.comEpilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJuly 15, 2025 | theglobeandmail.comStoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years agoJuly 15, 2025 | finance.yahoo.comThe charming Stoke-on-Trent four-bed family home that's 'ready to be lived in'July 13, 2025 | msn.comNew Royal Stoke technology cuts hospital stays by over a dayJuly 13, 2025 | msn.comGrit bin raiders and double parking hinders work to keep Stoke-on-Trent moving in winterJuly 13, 2025 | msn.comFive of the best beer gardens around Stoke-on-Trent to enjoy in the sunJuly 13, 2025 | msn.comMan City prospect told to gain notoriety at Stoke CityJuly 13, 2025 | msn.comLille rival Aston Villa in race for Stoke’s Sol SidibéJuly 10, 2025 | sports.yahoo.comAston Villa want Stoke City midfielder Sol SidibeJuly 10, 2025 | sports.yahoo.comCouncil still against Stoke-on-Trent 'merger' as devolution decision gets nearerJuly 10, 2025 | msn.comStoke City close in on fourth summer signingJuly 10, 2025 | msn.comStoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10, 2025 | businesswire.comBiogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10, 2025 | globenewswire.comPolice helicopter tracks 4 masked kids on stolen motorbikes in Stoke-on-Trent parkJuly 8, 2025 | msn.comStoke-on-Trent firm collapses into administrationJuly 8, 2025 | msn.comDriver dies in Royal Stoke after hitting treeJuly 8, 2025 | msn.comStoke City move early for 'lethal' rising Manchester City star in second signing of the dayJuly 7, 2025 | msn.comNew Hanford waste incinerator could keep patients warm at Royal StokeJuly 7, 2025 | msn.comStoke sign Talovierov and Man City's MubamaJuly 7, 2025 | msn.com Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Media Mentions By Week STOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.630.61▲Average Medical News Sentiment STOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼275▲STOK Articles Average Week Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MOR News NAMS News AMRX News RARE News KYMR News IMVT News HCM News XENE News ALVO News CRNX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STOK) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access